<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04657315</url>
  </required_header>
  <id_info>
    <org_study_id>CHAMC 2019-08-022</org_study_id>
    <nct_id>NCT04657315</nct_id>
  </id_info>
  <brief_title>Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients</brief_title>
  <acronym>MSC11FCD-GBM</acronym>
  <official_title>Investigator-initiated and Open-labeled Clinical Trial for Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHA University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CHA University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I trial evaluating the maximum tolerated dose, safety and efficiency of&#xD;
      Mesenchymal stem cells into which the suicide gene, cytosine deaminase (CD), injected into&#xD;
      the resection cavity of patients with recurrent glioblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not Provided&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 24, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>after treatment discontinuation for approximately 1 years</time_frame>
    <description>Assessment of the maximum tolerated dose based on the 3+3 method&#xD;
Blood concentrations of 5-FC and 5-FU(Day 1, Day 3, Day 7)&#xD;
MSC11FCD concentrations (MSCCD detection) (Day 0, 3months, 6months, 12months)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number Of Adverse Events related to the treatment</measure>
    <time_frame>Baseline, Day0, 1 month, 3 months, 6 months, 12 months</time_frame>
    <description>Evaluate the number of adverse event related to the treatment according to CTCAE V4.0 during the trial (including clinically significant changes in physical examination, radiographic images, safety lab tests, vital signs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival improvement (OS)</measure>
    <time_frame>Study entry through the end of the study, up to 12 months</time_frame>
    <description>OS is defined as the time from the date of MSC injection to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Study entry through the end of the study, up to 12 months</time_frame>
    <description>The progress-free survival analysis shall be based on the RANO criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor assessment in regard to the investigational drug based on the RANO criteria</measure>
    <time_frame>At Baseline, 1month, 3months, 6months, 12months</time_frame>
    <description>Assess the treatment groups participating in this clinical trial based on the RANO criteria.&#xD;
Compare and present the disease control rates by calculating the ratio of the number of subjects responding to treatment (complete response: CR, partial response: PR, stable disease: SD) among the treatment groups and control group assessed based on the RANO criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy assessment</measure>
    <time_frame>At Baseline, 1month, 3months, 6months, 12months</time_frame>
    <description>Karnofsky performance status (KPS) assessment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Neoplasms, Brain</condition>
  <condition>Neoplasms, Germ Cell and Embryonal</condition>
  <condition>Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>The investigational drug into the Intratumoral administration</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The investigational drug in the amount of 1x10^7, 3x10^7cells per dose into the tumor or the tumor removal site using a syringe during surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSC11FCD</intervention_name>
    <description>Administration period: Single dose Route of administration: Intratumoral administration Dose: 1x10^7, 3x10^7cells/dose Summary: Administer the investigational drug in the amount of 1x107, 3x107cells per dose into the tumor or the tumor removal site using a syringe during surgery.&#xD;
Concomitant drug: 5-Flucytosine (prodrug) Dose: 150mg/kg/day&#xD;
Directions:&#xD;
Administration period and directions: Administer 150m of 5-Flucytosine per kilogram of body weight every 6 hours for a total of 4 times a day (QID) for a duration of 7 days after surgery.&#xD;
Route of administration: Oral administration</description>
    <arm_group_label>The investigational drug into the Intratumoral administration</arm_group_label>
    <other_name>Mesenchymal stem cells into which the suicide gene, cytosine deaminase (CD)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 19 to 70&#xD;
&#xD;
          2. Patients diagnosed with recurrent glioblastoma based on medical imaging after&#xD;
             receiving standard therapy for glioblastoma&#xD;
&#xD;
          3. Patients scheduled to undergo surgical treatment for recurrent glioblastoma&#xD;
&#xD;
          4. Patients diagnosed with recurrent glioblastoma based on medical imaging (MRI:&#xD;
             conventional, diffusion, perfusion, spectroscopy) and confirmed to have tumor cells&#xD;
             during surgery based on frozen biopsy&#xD;
&#xD;
          5. Patients whose expected survival period is at least 3 months&#xD;
&#xD;
          6. Patients who have not received any other types of immunotherapy&#xD;
&#xD;
          7. Patients who have been given a sufficient explanation of the purpose and details of&#xD;
             the clinical trial and the characteristics of the investigational drug from an&#xD;
             investigator and who signed the consent form or had a legal guardian or representative&#xD;
             sign the consent form prior to the beginning of this clinical trial&#xD;
&#xD;
          8. Patients who have waited for at least four weeks after treatment using cytotoxic drugs&#xD;
             in order to eliminate the possibility of impact and effects from other therapeutic&#xD;
             agents (23 days after the last administration in case of undergoing standard therapy&#xD;
             using temozolomide)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have primary glioblastoma&#xD;
&#xD;
          2. Patients with dihydropyrimidine dehydrogenase (DPD) deficiency&#xD;
&#xD;
          3. Patients who cannot undergo a contrast (gadolinium) enhanced MRI scan due to a certain&#xD;
             condition (pacemaker, etc.) or cannot undergo an MRI scan according to the clinical&#xD;
             trial schedule due to any other reasons&#xD;
&#xD;
          4. Patients to whom Gliadel water was applied during surgery&#xD;
&#xD;
          5. Patients who are deemed to have a serious dysfunction in any of the major organs&#xD;
             (liver, kidneys, bone marrow, lungs, heart) by the investigator&#xD;
&#xD;
          6. Patents who have other types of malignant tumor aside from glioblastoma or who have&#xD;
             had malignant tumor in the past 5 years&#xD;
&#xD;
          7. Patients who uncontrolled hypotension or hypertension&#xD;
&#xD;
          8. Diabetic patients who are currently receiving insulin therapy or who need insulin&#xD;
             therapy&#xD;
&#xD;
          9. Patients who are deemed to have a serious infectious disease by the investigator:&#xD;
             sepsis, hepatitis A, hepatitis B or hepatitis C (in the case of hepatitis B and C&#xD;
             viruses, however, carriers may be enrolled at the investigator's discretion) or tested&#xD;
             positive in a serological test for the human immunodeficiency virus (HIV)&#xD;
&#xD;
         10. Karnofsky Performance Scale &lt; 60&#xD;
&#xD;
         11. Patients with an autoimmune disease affecting the central nervous system (multiple&#xD;
             sclerosis, myasthenia gravis, acute disseminated encephalomyelitis, etc.)&#xD;
&#xD;
         12. Patients with a history of allergic reactions to flucytosine (5-FC) and/or its&#xD;
             excipients or 5-fluorouracil (5-FU)&#xD;
&#xD;
         13. Pregnant or lactating women or patients who plan on getting pregnant during the&#xD;
             clinical trial or refuses to choose an appropriate method of contraception&#xD;
&#xD;
         14. Patients who have participated in a different clinical trial no more than 30 days&#xD;
             prior to registering for this clinical trial&#xD;
&#xD;
         15. Patients who are deemed to be unfit for this clinical trial by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyunggi Cho, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHA University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bundang CHA Medical Center</name>
      <address>
        <city>Seongnam</city>
        <state>Kyunggido</state>
        <zip>13496</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CHA University</investigator_affiliation>
    <investigator_full_name>Kyung GI, CHO</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Glioblastoma, Mesenchymal stem cells</keyword>
  <keyword>Brain Tumor</keyword>
  <keyword>Neoplasms, Germ Cell</keyword>
  <keyword>Flucytosine</keyword>
  <keyword>Central Nervous System Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

